Tiziana Life Sciences Ltd., which is developing the intranasal fully human anti-CD3 monoclonal antibody foralumab for neurological indications, has reported results from studies using a nasal anti-CD3 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback